#OP0049 corevitas observational registry: ax-SpA patients showed younger age, more males, greater spinal pain, more exposure to cs- or bDMARD but similar fatigue and work impairment compared to ax-PsA #EULAR2021 @RheumNow

#EULAR2021: If we review ASAS40 response from infliximab to tofacitinib, then there has not been much evolution in efficacy of therapy for SpA in the past 20 yrs. This suggests we haven't been looking at the right endpoint in measuring efficacy! MDA instead! @RheumNow https://t.co/E61yb97CRN

#Eular2021: Do you start a bDMARD for nr-AxSpa without objective evidence of inflammation (elevated CRP, negative structural damage on MRI)? @RheumNow

Novel Results from the @rheum_covid register in #RA patients presented by @jeffsparks #OP0006 Higher risk for patients on rituximab or on JAK inhibitors for hospitalisation & ventilation or death after #COVID19 infection compared to TNFi users. #EULAR2021 @RheumNow https://t.co/40h5zVpxAO

Can we taper IV belimumab in #SLE? Dr Fredi reported 14/48 (29%) extended tx to at least 5-weekly after 12mo of tx. No worsening C3/C4 & PGA but interestingly #steroid and SLEDAI ⬇️. More works needed to identify suitable pts for taper and regime #EULAR2021 #POS0107 @RheumNow https://t.co/Gwe7mPWPdY

Do look out for Abst #OP0057 today 2/6/21 1645 CEST #EULAR2021. We propose a data-driven algorithm for #rituximab maintenance in #ANCA #vasculitis to avoid excessive retreatment and low IgG @RheumJArn @edvital P. Emery @LeedsMedHealth @LTHTResearch @LeedsHospitals @LeedsBRC https://t.co/XRR0NFnpMu

🚨So after LoVAS Now this Ritux + MMF + Pulse MPS No oral steroids 🤯 @ARD_BMJ @EBRheum - Lesser is better ?? https://t.co/CYMNX8wLtd https://t.co/NtwTas3ZdS

• https://ard.bmj.com/content/72/8/1280.long

Positive RCT of Rituximab in Systemic sclerosis https://t.co/WsDZeollu0

• https://twitter.com/TheLancetRheum/status/1399748852295557123

Dr Atienza-Mateo presents on IFX ADA TCZ in Behcets refractory uveitic cystoid macular oedema. All appear effective! @RheumNow #EULAR2021 Abstr#OP0060 https://t.co/Vpju0IvrC5

Dr Mekinian presents data showing TCZ and TNFi appear equally effective in TAK, complete response 66% vs 70% at 6 months @RheumNow #EULAR2021 Abstr#OP0068